Clinical development failure
Cell therapy and oncology assets may not demonstrate safety or efficacy in trials.
- Scope
- Pipeline programs
- Materiality
- high
Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc. is a U.S.-based biopharmaceutical and technology holding company focused on acquiring, developing, and commercializing cell therapy technologies for cancer and other diseases. Through subsidiaries including Coeptis Therapeutics, Inc., SNAP Biosciences, Inc., and GEAR Therapeutics, Inc., it is shifting away from legacy generic drug activities toward innovative therapies and strategic development partnerships.
4
4.16
3.60
| % | |
|---|---|
| Cell therapy technologies | 60% Development and commercialization of cell-based therapies targeting cancer and other diseases. |
| Strategic partnerships and co-development | 20% Collaborations to advance autoimmune and oncology assets with external partners. |
| Legacy pharmaceutical products | 5% Previously commercialized 505(b)(2) anti-hypertension products that have since been abandoned. |
| Platform and holding company activities | 15% Subsidiary oversight, IP ownership, and corporate development activities supporting the portfolio. |
The company’s end customers are healthcare providers, patients, and ultimately payers in oncology, autoimmune, and...
- Oncology providers and treatment centersprimary
Buy or adopt cell therapy solutions for cancer care because they need differentiated treatment options.
- Strategic pharmaceutical partnersprimary
Partner on development and commercialization to share risk, expertise, and market access.
- Autoimmune therapy collaboratorssecondary
Work with the company on co-development programs for immune-mediated diseases.
- Healthcare distributors and marketing partnerssecondary
Support launch and promotion of products where the company lacks a large direct commercial footprint.
The company states that its products and technologies are intended to be commercialized in the U.S...
- •U.S. is the core operating and commercialization market
- •Targets other major global markets through future commercialization
- •No country-level revenue disclosure provided in the excerpts
- •Regulatory and clinical execution are anchored in the United States
- •International reach depends on partners and market approvals
Management is repositioning the company around innovative cell therapy and oncology-focused assets after exiting legacy...
01
Focus on cell therapy and oncology developmentmedium-term
These programs are the core of the company’s future value creation after exiting older product lines.
02
Expand strategic partnershipsshort-term
Partnerships provide technical capability, funding leverage, and commercialization support for a small biopharma platform.
03
Build a scalable holding-company platformmedium-term
A structured subsidiary base helps manage IP, development programs, and future acquisitions.
The company faces typical development-stage biopharma risks, including clinical failure, regulatory delays, and...
Regulatory approval delays
Biopharma products require extensive FDA and other regulatory review before commercialization.
- Scope
- U.S. and global commercialization plans
- Materiality
- high
Financing and dilution risk
Development-stage operations and professional fees can require repeated capital raises.
- Scope
- Corporate funding and operating runway
- Materiality
- high
Partner and commercialization execution risk
The company relies on strategic partners for development and market access, reducing direct control.
- Scope
- Co-development and launch activities
- Materiality
- high
Reverse merger accounting
Historical financial statements and trend analysis
Stock-based compensation
Operating expenses and diluted share count
Warrant-related financing costs
General and administrative expense and non-operating items
Professional fee accruals
Quarterly expense volatility
DYADIC INTERNATIONAL INC
DYAI · Biological Products, (No Diagnostic Substances)
Dyadic International is a U.S.-based biotechnology platform company that develops microbial protein production systems for industrial, life sciences, food and…
Xeris Biopharma Holdings, Inc.
XERS · Pharmaceutical Preparations
GALECTIN THERAPEUTICS INC
GALT · Pharmaceutical Preparations
C4 Therapeutics, Inc.
CCCC · Biological Products, (No Diagnostic Substances)
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
Citius Pharmaceuticals, Inc.
CTXR · Pharmaceutical Preparations
: 28.4.2026